uploads///Immunology dermatology

Investor Updates on Novartis’s Immunology and Dermatology Portfolio

By

Updated

Neoral/Sandimmune revenue trends

In 1H17, Novartis’s (NVS) Neoral/Sandimmune reported revenues of around $238 million, which reflected an ~8% decline on a year-over-year (or YoY) basis. In 2Q17, Neoral generated revenues of around $123 million, which reflected ~10% growth on a YoY basis and ~7% growth on a quarter-over-quarter basis. Neoral/Sandimmune (cyclosporine capsules) is used for the prevention of organ rejection in kidney, liver, and heart allogeneic transplants.

Article continues below advertisement

Zortress/Certican revenue trends

In 1H17, Novartis’s Zortress reported revenues of around $191 million, which is a ~1% decline on a YoY basis. In 2Q17, Zortress generated revenues of around $100 million, which reflected a ~2% decline on a YoY basis and 10% growth on a quarter-over-quarter basis. Zortress (everolimus) is used for the prevention of organ rejection in patients that underwent kidney or liver transplants. Kidney transplant patients are administered Zortress in combination with cyclosporine, basiliximab, and corticosteroids.

Myfortic revenue trends

In 1H17, Novartis’s Myfortic reported revenues of around $180 million, which is an ~8% decline on a YoY basis. In 2Q17, Myfortic generated revenues of around $98 million, which reflected ~8% growth on a YoY basis and 20% growth on a quarter-over-quarter basis.

Myfortic (mycophenolic acid) is used for the prevention of organ rejection in adult patients after a kidney transplant. Myfortic is administered to pediatric patients aged five years or above.

Ilaris revenue trends

In 1H17, Ilaris reported revenues of around $180 million, which is ~33% growth on a YoY basis. In 2Q17, Ilaris generated revenues of around $98 million, which reflected ~34% growth on a YoY basis and 20% growth on a quarter-over-quarter basis.

Ilaris (canakinumab) is used for the treatment of individuals with Cryopyrin-Associated Periodic Syndromes, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome (or HIDS)/Mevalonate Kinase Deficiency (or MKD), Familial Mediterranean Fever, and Active Systemic Juvenile Idiopathic Arthritis.

Novartis’s peers in immunology drugs market include Amgen (AMGN), AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson, Merck, Astellas, and others. The Vanguard International High Dividend Yield ETF (VYMI) invests ~1.4% of its total portfolio holding in Novartis.

Advertisement

More From Market Realist